Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Katz

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Therapeutic Innovation & Regulatory Science|November 6, 2018
21st-Century Oncology Drug Safety via New-Age Regulatory Standards and PracticesPeter J Pitts, Hervé Le Louet, Gregory Katz
JAMA Ophthalmology|April 13, 2013
Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%Gregory Katz, Harvey Dubiner, John Samples, et al.
Current Medical Research and Opinion|September 24, 2004
Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprostMartin Kaback, John Geanon, Gregory Katz, et al.
The Israel Medical Association Journal : IMAJ|August 4, 2011
A comparative study of psychiatric inpatients in a general hospital and a psychiatric hospital in Israel: demographics, psychopathological aspects and drug abuse patternsGregory Katz, Rimona Durst, Emi Shufman, et al.
Comprehensive Psychiatry|November 26, 2009
Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatientsGregory Katz, Rimona Durst, Emi Shufman, et al.
Comprehensive Psychiatry|January 15, 2002
Time zone change and major psychiatric morbidity: the results of a 6-year study in JerusalemGregory Katz, H Y Knobler, Z Laibel, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 15, 2010
Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprostGregory Katz, Clark L Springs, E Randy Craven, et al.
The Israel Medical Association Journal : IMAJ|November 18, 2008
Substance abuse in hospitalized psychiatric patientsGregory Katz, Rimona Durst, Emi Shufman, et al.
The Israel Journal of Psychiatry and Related Sciences|May 12, 2017
Cannabis and Alcohol Abuse Among First Psychotic Episode InpatientsGregory Katz, Yehuda Kunyvsky, Tzipi Hornik-Lurie, et al.
American Journal of Ophthalmology|March 5, 2016
A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004Robert M Feldman, Gregory Katz, Matthew McMenemy, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Therapeutic Innovation & Regulatory Science|November 6, 2018
21st-Century Oncology Drug Safety via New-Age Regulatory Standards and PracticesPeter J Pitts, Hervé Le Louet, Gregory Katz
JAMA Ophthalmology|April 13, 2013
Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%Gregory Katz, Harvey Dubiner, John Samples, et al.
Current Medical Research and Opinion|September 24, 2004
Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprostMartin Kaback, John Geanon, Gregory Katz, et al.
The Israel Medical Association Journal : IMAJ|August 4, 2011
A comparative study of psychiatric inpatients in a general hospital and a psychiatric hospital in Israel: demographics, psychopathological aspects and drug abuse patternsGregory Katz, Rimona Durst, Emi Shufman, et al.
Comprehensive Psychiatry|November 26, 2009
Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatientsGregory Katz, Rimona Durst, Emi Shufman, et al.
Comprehensive Psychiatry|January 15, 2002
Time zone change and major psychiatric morbidity: the results of a 6-year study in JerusalemGregory Katz, H Y Knobler, Z Laibel, et al.
Clinical Ophthalmology (Auckland, N.Z.)|December 15, 2010
Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprostGregory Katz, Clark L Springs, E Randy Craven, et al.
The Israel Medical Association Journal : IMAJ|November 18, 2008
Substance abuse in hospitalized psychiatric patientsGregory Katz, Rimona Durst, Emi Shufman, et al.
The Israel Journal of Psychiatry and Related Sciences|May 12, 2017
Cannabis and Alcohol Abuse Among First Psychotic Episode InpatientsGregory Katz, Yehuda Kunyvsky, Tzipi Hornik-Lurie, et al.
American Journal of Ophthalmology|March 5, 2016
A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004Robert M Feldman, Gregory Katz, Matthew McMenemy, et al.
Pageof 4